Vertex Pharmaceuticals 주식 (NASDAQ: VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) 주식

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

wall street ai15

Education

Econ #s

VRTX

2025년 1분기에 가장 성과가 좋았던 S&amp;P 500 주식 다섯 종목은 CVS 헬스(NYSE:CVS), 필립모리스(NYSE:PM), 뉴몬트(NYSE:NEM), 센코라(NYSE:COR), 그리고 버텍스 파마슈티컬스(NASDAQ:VRTX)이며, 이들은 최근 며칠 동안 단지 미미한 하락만 겪었다. 무역 긴장과 경기 침체에 대한 우려로 S&amp;P 500 지수가 10% 급락한 것과는 대조적이다. 

S&amp;P 500 종목 중 2025년 1분기에 강세 보인 5개 주식...랠리 지속될까?

McDonald's Launches Limited-Edition Holiday Cups Co-Branded With Doodles

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

VOXX

월요일(10일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 맥도날드, 온 세미컨덕터, 복스 인터내셔널, 로크웰 및 버텍스

월요일 주목해야 할 주식: 맥도날드, 온 세미컨덕터, 복스 인터내셔널, 로크웰 및 버텍스

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Health Care

Technicals

General

버텍스 파마슈티컬스(NASDAQ:VRTX)는 주가가 악성 데스 크로스(Death Cross)를 형성하면서 하락세 기술 신호를 받고 있다.

버텍스의 주가는 데스 크로스를 형성한 약세 차트와 힘겨루기 중

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.31.
Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.04, which was followed by a 3.14% drop in the share price the next day.
Here's a look at Vertex Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>4.02</td>
<td>4.14</td>
<td>4.14</td>
<td>4.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.98</td>
<td>4.38</td>
<td>-12.83</td>
<td>4.76</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>6.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746219725_0.png" alt="eps graph" />
<h3>Vertex Pharmaceuticals Share Price Analysis</h3>
Shares of Vertex Pharmaceuticals were trading at $498.86 as of May 01. Over the last 52-week period, shares are up 24.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about Vertex Pharmaceuticals</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Vertex Pharmaceuticals.
The consensus rating for Vertex Pharmaceuticals is Neutral, derived from 12 analyst ratings. An average one-year price target of $473.92 implies a potential 5.0% downside.
<h3>Comparing Ratings with Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Gilead Sciences, Amgen and Regeneron Pharmaceuticals, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Gilead Sciences, with an average 1-year price target of $118.81, suggesting a potential 76.18% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Amgen, with an average 1-year price target of $311.17, suggesting a potential 37.62% downside.</li>
<li>Analysts currently favor an Buy trajectory for Regeneron Pharmaceuticals, with an average 1-year price target of $790.94, suggesting a potential 58.55% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for Gilead Sciences, Amgen and Regeneron Pharmaceuticals, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vertex Pharmaceuticals</td>
<td>Neutral</td>
<td>15.66%</td>
<td>$2.49B</td>
<td>5.70%</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>Outperform</td>
<td>-11.92%</td>
<td>$5.99B</td>
<td>6.85%</td>
</tr>
<tr>
<td>Amgen</td>
<td>Neutral</td>
<td>10.86%</td>
<td>$5.97B</td>
<td>9.36%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>Buy</td>
<td>-3.70%</td>
<td>$2.56B</td>
<td>2.75%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Vertex Pharmaceuticals ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>Discovering Vertex Pharmaceuticals: A Closer Look</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Breaking Down Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Vertex Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 15.66%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 31.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 5.7%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 4.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/VRTX/earnings">To track all earnings releases for Vertex Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Vertex Pharmaceuticals

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/30/final-trades-berkshire-hathaway-vertex-pharma-sp-global-and-cme-group.html">Halftime Report Final Trades</a>,&#8221; Jim Lebenthal of Cerity Partners named Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) as his final trade ahead of its quarterly <a href="https://www.benzinga.com/quote/BRK.B/analyst-ratings">earnings report on Saturday</a>.
On April 25, UBS analyst Brian Meredith maintained a Buy rating for Berkshire Hathaway and raised the price target from $557 to $606.
Stephen L. Weiss of Short Hills Capital Partners picked Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) as his final trade.
Lending support to his choice, Cantor Fitzgerald analyst Carter Gould, on April 22, initiated coverage of Vertex Pharmaceuticals with an Overweight rating and announced a price target of $535.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Karen Firestone of Aureus Asset Management said S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) reported a great quarter.
S&amp;P Global reported quarterly adjusted earnings per share of $4.37 on Tuesday, beating the analyst consensus estimate of $4.19 per share. Quarterly sales of $3.78 billion (up 8% year over year) outpaced the street view of $3.70 billion. Revenue from subscription products increased 7%.
Joseph M. Terranova of Virtus Investment Partners said he likes CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>).
On the earnings front, CME Group posted first-quarter adjusted earnings of $2.80 per share on April 23, beating market estimates of $2.79 per share. The company's quarterly sales came in at $1.60 billion versus expectations of $1.64 billion.
Price Action:
<ul>
<li>Berkshire Hathaway shares fell 0.3% to close at $533.25 on Wednesday.</li>
<li>Vertex Pharmaceuticals gained 1.2% to close at $509.50 during Wednesday's session.</li>
<li>S&amp;P Global gained 1.7% to close at $500.05 on Wednesday.</li>
<li>CME Group shares climbed 1.7% to settle at $277.08 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/45098110/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo: Shutterstock

Media

SPGI

S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades'

Analyst Ratings

BRK/B

CNBC Halftime Report Final Trades: Berkshire Hathaway - B Shares, Vertex Pharmaceuticals, S&P Global, CME Group

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 10 years by 4.96% on an annualized basis producing an average annual return of 15.22%. Currently, Vertex Pharmaceuticals has a market capitalization of $129.20 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,986.54 today based on a price of $503.15 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745959511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion For Vertex Pharmaceuticals' Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor) For Cystic Fibrosis Patients Aged 6 Years And Older Who Have At Least One Non-class I Mutation In The Cystic Fibrosis Transmembrane Conductance Regulator Gene.

Ratings for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $479.06, with a high estimate of $567.00 and a low estimate of $407.00. This current average has increased by 2.98% from the previous average price target of $465.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1745323218_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Vertex Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Carter Gould &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Overweight &#x7C; $535.00&#x7C;- &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $420.00&#x7C;$408.00 &#x7C; 
&#x7C;Ying Huang &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $567.00&#x7C;$555.00 &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $408.00&#x7C;$407.00 &#x7C; 
&#x7C;Whitney Ijem &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Hold &#x7C; $424.00&#x7C;$408.00 &#x7C; 
&#x7C;Joon Lee &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $520.00&#x7C;$460.00 &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $407.00&#x7C;$402.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $450.00&#x7C;$433.00 &#x7C; 
&#x7C;Olivia Brayer &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $480.00&#x7C;$480.00 &#x7C; 
&#x7C;Gena Wang &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $467.00&#x7C;$435.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $550.00&#x7C;$550.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $459.00&#x7C;$450.00 &#x7C; 
&#x7C;Olivia Brayer &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $480.00&#x7C;$480.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $433.00&#x7C;$430.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $550.00&#x7C;$535.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $460.00&#x7C;$460.00 &#x7C; 
&#x7C;Christopher Raymond &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $533.00&#x7C;$535.00 &#x7C; 
&#x7C;Olivia Brayer &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $480.00&#x7C;$480.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vertex Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Vertex Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vertex Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Discovering Vertex Pharmaceuticals: A Closer Look</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Vertex Pharmaceuticals's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 15.66%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 31.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.7% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.08% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts

Cantor Fitzgerald analyst Carter Gould assumes Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight rating and announces Price Target of $535.

Price Target

Initiation

Cantor Fitzgerald Assumes Vertex Pharmaceuticals at Overweight, Announces Price Target of $535

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is <a href="https://www.benzinga.com/quote/VRTX/earnings">entering earnings week</a> with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 12 months. But with a 3.5% pullback in the past month, all eyes are now on its first-quarter report, expected to drop shortly on May 5, after market hours.
<h1 class="wp-block-heading">Alyftrek and Journavx — The Two Big Launches</h1>
According to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company&#8217;s two big launches: Alyftrek and Journavx. While Vertex's cystic fibrosis heavyweight Trikafta is still expected to bring in the bulk of first quarter revenue — $2.51 billion of the $2.74 billion total JPMorgan is modeling — international headwinds, particularly from Russia's disregard of IP rights, could muddy the picture.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/04/44670084/vertexs-journavx-launch-sparks-optimism-analyst-sees-two-potential-upside-levers">Vertex&#8217;s Journavx Launch Sparks Optimism, Analyst Sees &#8216;Two Potential Upside Levers&#8217;</a>
The wildcards? Alyftrek and Journavx. JPMorgan pegs Alyftrek at $50 million in sales and Journavx at less than $1 million, but says upside surprises could emerge if there's more channel stocking or better-than-expected uptake. IQVIA script trends for Journavx, while early, have already outpaced what Fye calls "low investor expectations." 
What remains to be seen is where the uptake is coming from — retail or hospitals — and how insurance coverage and patient types shake out.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21133056/Screenshot-2025-04-21-at-11.00.43-PM.png" alt="" class="wp-image-880332" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21133056/Screenshot-2025-04-21-at-11.00.43-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21133056/Screenshot-2025-04-21-at-11.00.43-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
On the charts, Vertex stock is technically leaning bullish. It&#8217;s trading above its 20-day, 50-day and 200-day simple moving averages, although just barely below its eight-day SMA. The Moving Average Convergence Divergence (MACD) and slight buying pressure suggest cautious optimism, despite the stock's recent cool-down.
Bottom line? 
With multiple pipeline catalysts and the first quarter potentially validating new product momentum, Vertex could quickly recapture investor enthusiasm — or leave analysts recalibrating expectations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has fallen 22.32% since its last report. The company recently reported that it has 4.46 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744894853_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Vertex Pharmaceuticals's Recent Short Interest

US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reduce Medicare costs</a>.
Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028.
<ul>
<li>This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.</li>
<li>Additionally, the administration seeks to eliminate a key disparity in how Medicare treats small-molecule drugs compared to biologics, discouraging investment in more affordable treatments.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
The White House is also <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/" rel="noreferrer noopener">targeting</a> the rising costs seniors face under Medicare. A new payment model will be tested within a year to obtain better value for high-cost drugs and biologicals, including those not subject to price negotiations.
Further, the administration wants to align Medicare payments with actual hospital acquisition costs through a national survey, with potential reimbursement adjustments following the results.
To reform Medicaid drug pricing, the administration will develop recommendations linking drug payments to their value and ensuring accurate rebate payments from manufacturers. The initiative also aims to assist states in managing spending while promoting innovation in Medicaid reimbursement.
Affordability for life-saving medications is another key focus: Community health centers will be required to offer insulin and epinephrine at or below discounted 340B prices to low-income individuals with high out-of-pocket costs or no insurance, with compliance tied to eligibility for future federal grants..
To address price manipulation in the supply chain, the administration calls for reevaluating middlemen roles, such as pharmacy benefit managers, and seeking transparency in their compensation structures. Within 90 days, recommendations to promote a more efficient pharmaceutical market are expected.
Other planned reforms include accelerating FDA approvals for generics and over-the-counter conversions, streamlining the drug importation program, and ensuring Medicare payments do not incentivize hospital-based care over less costly physician offices.
Lastly, federal agencies will investigate anti-competitive practices by drug manufacturers, with public listening sessions and policy recommendations expected within six months.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo by Aria Armoko via Shutterstock

Government

Regulations

ABBV

BIIB

BMRN

GILD

REGN

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction

On CNBC's <a href="https://www.cnbc.com/video/2025/04/10/final-trades-vertex-robinhood-palo-alto-and-crowdstrike.html">&#8220;Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management picked CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>).
On Wednesday, CrowdStrike announced an expansion of its partnership with Alphabet Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google Cloud to enable end-to-end security for AI innovation with the company's Falcon Cloud Security platform.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
Brenda&nbsp;Vingiello of Sand Hill Global Advisors named Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), saying the first non-opioid pain medication <a href="https://www.benzinga.com/quote/VRTX/earnings">will be a game changer</a>.
Vertex Pharmaceuticals will report its first-quarter financial results on Monday, May 5, after the closing bell.
Bryn Talkington of Requisite Capital Management picked Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) as her final trade.
On the earnings front, Robinhood Markets will release its first quarter financial results on Wednesday, April 30, after the closing bell. Analysts expect the company to report quarterly earnings at 37 cents per share on revenue of $909.41 million.
Stephanie Link of Hightower named Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), a cybersecurity stock.
Supporting her view, HSBC analyst Stephen Bersey, on Thursday, upgraded Palo Alto Networks from Reduce to Hold and announced a $156 price target.
Price Action:
<ul>
<li>Vertex Pharmaceuticals shares fell 1.4% to close at $475.49 on Thursday.</li>
<li>Robinhood shares dipped 4% to close at $40.51 during Thursday's session.</li>
<li>CrowdStrike shares fell 2.5% to close at $368.61 on Thursday.</li>
<li>Palo Alto Networks fell 2.8% to settle at $168.27 during Thursday's session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Image: Shutterstock

CRWD

GOOG

HOOD

PANW

CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'

UPDATE: CNBC Halftime Report Final Trades: Vertex Pharmaceuticals, Robinhood Markets, Palo Alto Networks, CrowdStrike Holdings

Despite Wall Street continuing to tumble at the start of the second quarter of 2025, a small group of S&amp;P 500 stocks has remained nearly untouched by the chaos triggered by <a href="https://www.benzinga.com/topic/tariffs">Donald Trump's tariff policies.</a>
Stocks that delivered standout gains in the first quarter have held their ground through the opening week of the second quarter, showing resilience as the broader market sank under pressure from tariffs and softening earnings outlooks.
The five best-performing S&amp;P 500 names in Q1 2025 — CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Cencora Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) — have seen only minimal declines in recent days, defying a sharp 10% drop in the S&amp;P 500 index fueled by mounting trade tensions and concerns over recession. 
<h3 class="wp-block-heading">Quarterly Stars In A Cloudy Market</h3>
Let's break it down:
<ul>
<li>CVS Health soared 50.9% in Q1, posting its best quarterly gain since 1975. While the S&amp;P 500 dropped 10% in the first week of April, CVS is only down 5% in Q2.</li>
<li>Philip Morris jumped 31.9% last quarter, reaching multiple record highs and logging its second-best quarter since going public in 2008. PM is down 4.8% thus far in April.</li>
<li>Newmont rode the gold wave. With gold prices up 19%, the mining giant surged 29.7%, its strongest 3-month performance since early 2020. NEM fell 7.2% in Q2, yet showed a more contained drop than the broader market.</li>
<li>Cencora, formerly AmerisourceBergen, posted a 23.8% rise, and remains up 0.2% this month, dodging the tariff-driven downturn.</li>
<li>Vertex Pharmaceuticals climbed 21% in Q1, and has stayed flat so far in Q2, showing impressive stability in biotech.</li>
</ul>
<h3 class="wp-block-heading">But How Much More Room To Run?</h3>
Despite their impressive runs, future gains may be limited. Analyst consensus shows only Newmont and CVS have potential upside of 25.8% and 13.2%, respectively, based on median price targets. 
For the others, the path forward looks far less compelling. With valuations already stretched and macroeconomic risks mounting — from renewed trade tensions to signs of weakening corporate margins — the potential for further gains could quickly evaporate if analysts begin slashing forecasts in the coming weeks.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Q1 2025 Price Change</th>
<th>YTD Price Change</th>
<th>Median Target Upside</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health (CVS)</td>
<td>+50.9%</td>
<td>+43.71%</td>
<td>+13.16%</td>
</tr>
<tr>
<td>Philip Morris (PM)</td>
<td>+31.9%</td>
<td>+26.02%</td>
<td>+2.86%</td>
</tr>
<tr>
<td>Newmont Corporation (NEM)</td>
<td>+29.7%</td>
<td>+21.77%</td>
<td>+25.77%</td>
</tr>
<tr>
<td>Cencora Inc. (COR)</td>
<td>+23.8%</td>
<td>+23.78%</td>
<td>+0.68%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals (VRTX)</td>
<td>+21.0%</td>
<td>+19.20%</td>
<td>+6.66%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of April 7, 2025</figcaption></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">Emergency Fed Rate Cut Odds Spike As Trump Says &#8216;No Inflation,&#8217; Calls for Immediate Action</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?

Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is giving investors some good news — especially if they're keeping a close eye on its <a href="https://www.benzinga.com/quote/VRTX/news">newly launched painkiller Journavx</a>.
<h1 class="wp-block-heading">Journavx Gains Early Traction</h1>
At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor Relations Susie Lisa.
The message is that Journavx is off to a strong start in its acute pain debut, with good momentum across hospital and retail settings and broad shelf availability, reportedly on close to 90% of U.S. pharmacy shelves.
Coverage is picking up faster than anticipated, and while the drug is mostly placed in Tier 3 for now, management downplayed the concern. "It's all about overall value," they emphasized, as anecdotal reports suggest that both prescribing physicians and patients are seeing encouraging results.
Read Also: <a href="https://www.benzinga.com/insights/short-sellers/25/04/44591879/is-vertex-pharmaceuticals-gaining-or-losing-market-support">Is Vertex Pharmaceuticals Gaining or Losing Market Support?</a>
<h1 class="wp-block-heading">Two Levers To Watch In 2025</h1>
Fye highlighted that Vertex&#8217;s 2025 revenue guide of $11.75 billion to $12 billion is primarily powered by cystic fibrosis therapies, but she also noted "two potential upside levers" to that figure: 
<ul>
<li>A quicker-than-expected ramp-up for Journavx</li>
<li>Faster patient dosing for gene-editing therapy Casgevy.</li>
</ul>
The former is shaping up nicely already, while the latter, she noted, remains "a long journey."
<h1 class="wp-block-heading">Alyftrek and International Challenges</h1>
The company remains confident in Alyftrek, its next-gen cystic fibrosis drug with once-daily dosing and an expanded mutation profile.
There is, however, one international wrinkle: the expected revenue drag from Russia's disregard of Vertex's intellectual property rights. 
Still, with a high-quality profile and positive momentum in pain and gene therapy, Fye believes Vertex could continue to benefit from rotation in this macro backdrop.
JPMorgan reiterated its Overweight rating.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a></li>
</ul>
Photo: Shutterstock

Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'

<a href="https://news.vrtx.com/news-releases/news-release-details/european-commission-approves-expanded-label-kaftrior-combination" title="https://news.vrtx.com/news-releases/news-release-details/european-commission-approves-expanded-label-kaftrior-combination">https://news.vrtx.com/news-releases/news-release-details/european-commission-approves-expanded-label-kaftrior-combination</a>

Global

'European Commission Approves Expanded Label For KAFTRIO In Combination With Ivacaftor For People With Cystic Fibrosis'

Several exemptions exist among President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted" target="_blank" rel="noopener">broad tariffs</a>, which were announced on Wednesday. 
The biopharma industry has historically been shielded from tariffs, including during Trump&#8217;s first term. Given its significant manufacturing presence in Europe, investors had feared global tariffs could disrupt the sector.
Morningstar <a href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" target="_blank" rel="noopener">reports</a> that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the industry $20 billion, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44642463/french-president-macron-suggests-suspension-of-eu-investments-in-us-amid-tariff-turmoil" rel="noreferrer noopener">French President Macron Suggests Suspension Of EU Investments In US Amid Tariff Turmoil, Vows &#8216;More Powerful&#8217; Response</a>
Goldman Sachs expects continued volatility in the biotechnology sector (XBI and S&amp;P 500 are down about 14% and 7% year-to-date, respectively), driven by broader economic <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" rel="noreferrer noopener">uncertainty and unclear healthcare policy</a>.
Analyst Salveen Richter has analyzed geographic exposure and tax rates for individual companies and sees Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) in the strongest position, followed by Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often import ingredients or finished products into the U.S.
Analyst Richter adds that <a target="_blank" href="https://www.benzinga.com/quote/AMGN" rel="noreferrer noopener">Amgen</a>, <a target="_blank" href="https://www.benzinga.com/quote/ALNY" rel="noreferrer noopener">Alnylam</a>, <a target="_blank" href="https://www.benzinga.com/quote/BIIB" rel="noreferrer noopener">Biogen</a>, and <a target="_blank" href="https://www.benzinga.com/quote/REGN" rel="noreferrer noopener">Regeneron</a> are the least exposed to Medicaid risk.
Goldman Sachs said Friday that it&#8217;s been hard to measure the exact impact of potential tariffs on U.S. biopharma due to limited public data on where drugs are made.
Their analysis shows limited manufacturing exposure to Canada, Mexico and China. Pharmaceuticals from Canada and Mexico are also likely exempt under the USMCA trade deal. However, some companies do rely heavily on manufacturing in the EU.
If tariffs are placed on drugs made outside the U.S. and kept in place, they could raise manufacturing costs. Companies often import ingredients or finished products before selling them in the U.S. Some manufacturers are reportedly speeding up shipments from Europe out of concern that tariffs may apply to <a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noopener">those products,</a><a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noreferrer noopener"> too</a>.
Goldman Sachs is also watching for exceptions or phased rollouts, pointing to a similar eight-year grace period in the Biosecure Act.
Still, the analyst writes that biopharma companies are generally resilient due to their high profit margins and globally spread operations.
Companies that produce small-molecule drugs might handle a U.S. manufacturing shift better than those making biologics since small molecules require less complex production.
Senator Ron Wyden has raised concerns about Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) using offshore setups to reduce U.S. taxes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44648087/karman-strikes-90m-deal-for-mti-enhancing-position-in-next-gen-defense-technologies" target="_blank" rel="noreferrer noopener">Karman Strikes $90M Deal For MTI, Enhancing Position In Next-Gen Defense Technologies</a></li>
</ul>
Photo: Shutterstock

Large Cap

ALNY

AMGN

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 4.67% since its last report. The company recently reported that it has 5.75 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743529515_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Vertex Pharmaceuticals Gaining or Losing Market Support?

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $408 to $420.

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $420

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high estimate of $567.00, and a low estimate of $407.00. This upward trend is apparent, with the current average reflecting a 0.91% increase from the previous average price target of $473.82.
<img src="https://www.benzinga.com/files/images/story/2025/1743458443_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Vertex Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$567.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$408.00</td>
<td>$407.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$424.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$520.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$407.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$450.00</td>
<td>$433.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$467.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$459.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$433.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$460.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$533.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$460.00</td>
<td>$555.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vertex Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Vertex Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Vertex Pharmaceuticals Better</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Vertex Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 15.66%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 31.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.08%, the company showcases efficient use of assets and strong financial health.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) announced on Friday updates about its type 1 diabetes (T1D) portfolio.
The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44545391/vertex-announces-program-updates-for-type-1-diabetes-portfolio" rel="noreferrer noopener">including of explanted devices</a>.
<ul>
<li>Vertex completed enrollment and dosing in Parts A and B of the&nbsp;Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B.</li>
<li>In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunoprotective device.</li>
<li>In Part B, there were two primary endpoints: safety and change in peak C-peptide during a mixed-meal tolerance test (MMTT) from baseline at Day 90.</li>
<li>VX-264 was generally safe and well tolerated; however, the study did not meet the efficacy endpoint.</li>
<li>Increases in C-peptide, a marker of insulin production, were not observed at levels necessary to deliver benefit.</li>
</ul>
Zimislecel (formerly VX-880), Vertex&#8217;s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia.
<ul>
<li>The is on track to complete enrollment and dosing in the first half of 2025, setting up global regulatory submissions in 2026.</li>
</ul>
Vertex is investing in expanding its manufacturing and commercial capabilities to ensure launch readiness. If approved, eligible patients across the U.S. and Europe with recurrent SHEs despite best available care could benefit from zimislecel. Vertex anticipates that initial approval could serve approximately 60,000 people with severe T1D.
Vertex is also pursuing research-stage T1D programs. These approaches include alternative immunosuppressive regimens, gene-edited hypoimmune stem-cell derived islet cell therapies, and novel devices to encapsulate islet cells.
William Blair wrote,&#8221;We view the discontinuation of VX-264 as disappointing given that this would have expanded Vertex's type 1 diabetes market significantly from that being addressed from zimislecel; however, we did not ascribe any value for the early-stage program in our model. Vertex's prioritization on the clinical advancement and potential launch of zimislecel for 60,000 severe T1D patients is prudent given the positive data to date, and approval in the T1D space would serve to further the company's diversity of commercial assets beyond cystic fibrosis and acute pain.&#8221;
Analyst Myles Minter reiterated <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings" target="_blank" rel="noreferrer noopener">an Outperform rating</a>.
VRTX Price Action: Vertex stock was down 2.09% at $482.36 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44566809/eli-lillys-cholesterol-drug-reduces-genetic-heart-disease-risk-factor-by-93-9" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%</a></li>
</ul>
Photo: Shutterstock

Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data

Press Releases

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

AM Best Assigns Credit Ratings to Torreyana Insurance Company, Inc.

Vertex to Participate in Upcoming March Investor Conferences

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

Vertex to Announce First Quarter 2025 Financial Results on May 5th

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

COEP

RPRX

SMMT

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

Comments

Vertex Pharmaceuticals

뉴스

파트너 / 기고자

벤징가 글로벌